Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://camara.gov.co
Are you over 18 and want to see adult content?
A complete backup of https://scrimshanders.com
Are you over 18 and want to see adult content?
A complete backup of https://obesitycanada.ca
Are you over 18 and want to see adult content?
A complete backup of https://bmcargo.com
Are you over 18 and want to see adult content?
A complete backup of https://dpic.org
Are you over 18 and want to see adult content?
A complete backup of https://carlock.co
Are you over 18 and want to see adult content?
A complete backup of https://kidneyurology.org
Are you over 18 and want to see adult content?
A complete backup of https://coffee-mate.com
Are you over 18 and want to see adult content?
A complete backup of https://parkwestgallery.com
Are you over 18 and want to see adult content?
A complete backup of https://cloud.tencent.com
Are you over 18 and want to see adult content?
A complete backup of https://spiritanimalbk.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of everydayminerals.com
Are you over 18 and want to see adult content?
A complete backup of archbishopgomez.org
Are you over 18 and want to see adult content?
A complete backup of lafelicidadestadelante.com
Are you over 18 and want to see adult content?
A complete backup of bidinstrabane.com
Are you over 18 and want to see adult content?
A complete backup of 7segundos.com.br
Are you over 18 and want to see adult content?
Text
R&D Day.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST PROVIDES UPDATE ON GALIDESIVIR PROGRAM Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of Marburg virus disease. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including, Ebola, Marburg, Yellow Feverand Zika viruses.
BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HAE ORLADEYO ™ (berotralstat). ORLADEYO™ (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein. EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST PROVIDES UPDATE ON GALIDESIVIR PROGRAM Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of Marburg virus disease. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including, Ebola, Marburg, Yellow Feverand Zika viruses.
BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeXCORPORATE PROFILE
Corporate Profile. Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, contact us.BioCryst.
BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). BIOCRYST | ORAL DRUGS FOR VIRUSES | GALIDESIVIR Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST | ORAL DRUGS FOR FOP AND OTHER RARE DISEASES | FOP Fibrodysplasia Ossificans Progressiva (FOP) Pursuing activin receptor-like kinase-2 (ALK2) inhibition in the race to stop Fibrodysplasia Ossificans Progressiva (FOP). BIOCRYST REPORTS DATA FROM PHASE 1 TRIAL OF BCX9930 AND —Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated—PROXY ONLINE
BioCryst will first make available the proxy solicitation materials at www.proxyvote.com on or about April 13, 2021 to all stockholders entitled to vote at the annual meeting. You may also request a printed copy of the proxy solicitation materials by any of the following methods: via Internet at www.proxyvote.com; by telephone at1-800-579-1639
BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR —BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervoussystem —
BIOCRYST ANNOUNCES PARTNERSHIP WITH TORII PHARMACEUTICAL The Investor Relations website contains information about BioCryst Pharmaceuticals's business for stockholders, potential investors, andfinancial analysts.
BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HAE ORLADEYO ™ (berotralstat). ORLADEYO™ (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein. EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST PROVIDES UPDATE ON GALIDESIVIR PROGRAM Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of Marburg virus disease. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including, Ebola, Marburg, Yellow Feverand Zika viruses.
BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HAE ORLADEYO ™ (berotralstat). ORLADEYO™ (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein. EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST PROVIDES UPDATE ON GALIDESIVIR PROGRAM Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of Marburg virus disease. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including, Ebola, Marburg, Yellow Feverand Zika viruses.
BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeXCORPORATE PROFILE
Corporate Profile. Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, contact us.BioCryst.
BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). BIOCRYST | ORAL DRUGS FOR VIRUSES | GALIDESIVIR Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST | ORAL DRUGS FOR FOP AND OTHER RARE DISEASES | FOP Fibrodysplasia Ossificans Progressiva (FOP) Pursuing activin receptor-like kinase-2 (ALK2) inhibition in the race to stop Fibrodysplasia Ossificans Progressiva (FOP). BIOCRYST REPORTS DATA FROM PHASE 1 TRIAL OF BCX9930 AND —Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated—PROXY ONLINE
BioCryst will first make available the proxy solicitation materials at www.proxyvote.com on or about April 13, 2021 to all stockholders entitled to vote at the annual meeting. You may also request a printed copy of the proxy solicitation materials by any of the following methods: via Internet at www.proxyvote.com; by telephone at1-800-579-1639
BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR —BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervoussystem —
BIOCRYST ANNOUNCES PARTNERSHIP WITH TORII PHARMACEUTICAL The Investor Relations website contains information about BioCryst Pharmaceuticals's business for stockholders, potential investors, andfinancial analysts.
BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST | ORAL DRUGS FOR RARE DISEASES | PIPELINE BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst’s core development programs include: BCX9930, an oral Factor D inhibitor for the treatment ofcomplement-mediated
BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). MHRA GRANTS HAE PATIENTS EARLY ACCESS TO BIOCRYST’S RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST | ORAL DRUGS FOR RARE DISEASES | PIPELINE BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst’s core development programs include: BCX9930, an oral Factor D inhibitor for the treatment ofcomplement-mediated
BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). MHRA GRANTS HAE PATIENTS EARLY ACCESS TO BIOCRYST’S RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | ABOUT BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases. BioCryst’s US headquarters are located in Durham, North Carolina, our EuropeanCORPORATE PROFILE
Corporate Profile. Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, contact us.BioCryst.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HAE ORLADEYO ™ (berotralstat). ORLADEYO™ (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein. BIOCRYST | ORAL DRUGS FOR RARE DISEASE | LEADERSHIP The BioCryst leadership team brings a passion for science and commitment to collaboration. BIOCRYST | ORAL DRUGS FOR RARE DISEASES | CAREERS BioCryst offers a competitive salary and an excellent benefits package including insurance (medical, dental, vision, disability and life), 401 (k), paid time off, and equity participation. BioCryst is an equal opportunity employer and is committed to providing equal employment opportunities without regard to age, race, religion, sex, sexual BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST ANNOUNCES PARTNERSHIP WITH TORII PHARMACEUTICAL The Investor Relations website contains information about BioCryst Pharmaceuticals's business for stockholders, potential investors, andfinancial analysts.
BIOCRYST REPORTS DATA FROM PHASE 1 TRIAL OF BCX9930 AND —Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR —BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervoussystem —
BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST | ORAL DRUGS FOR RARE DISEASES | PIPELINE BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst’s core development programs include: BCX9930, an oral Factor D inhibitor for the treatment ofcomplement-mediated
BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HAE ORLADEYO ™ (berotralstat). ORLADEYO™ (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein.CORPORATE PROFILE
Corporate Profile. Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, contact us.BioCryst.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR —BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervoussystem —
BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST | ORAL DRUGS FOR RARE DISEASES | PIPELINE BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst’s core development programs include: BCX9930, an oral Factor D inhibitor for the treatment ofcomplement-mediated
BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HAE ORLADEYO ™ (berotralstat). ORLADEYO™ (berotralstat) is an oral, once-daily capsule that prevents hereditary angioedema (HAE) attacks by inhibiting plasma kallikrein.CORPORATE PROFILE
Corporate Profile. Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, contact us.BioCryst.
BIOCRYST SUBMITS MARKETING AUTHORIZATION APPLICATION FOR RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR —BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervoussystem —
BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | ABOUT BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases. BioCryst’s US headquarters are located in Durham, North Carolina, our European BIOCRYST | ORAL DRUGS FOR RARE DISEASE | LEADERSHIP The BioCryst leadership team brings a passion for science and commitment to collaboration. BIOCRYST | ORAL DRUGS FOR VIRUSES | GALIDESIVIR Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST | ORAL DRUGS FOR RARE DISEASES | CAREERS BioCryst offers a competitive salary and an excellent benefits package including insurance (medical, dental, vision, disability and life), 401 (k), paid time off, and equity participation. BioCryst is an equal opportunity employer and is committed to providing equal employment opportunities without regard to age, race, religion, sex, sexual BIOCRYST PHARMACEUTICALS, INC. 2 BioCryst Pharmaceuticals, Inc. FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE ORLADEYO. TM is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult s and pediatric patients 12 years of age and older . BIOCRYST PROVIDES UPDATE ON GALIDESIVIR PROGRAM Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of Marburg virus disease. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including, Ebola, Marburg, Yellow Feverand Zika viruses.
BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BIOCRYST | ORAL DRUGS FOR HAE AND OTHER RARE DISEASES | HOMECOMPANYOUR FOCUSCAREERSINVESTORS & MEDIALOGINLEADERSHIP TEAM BioCryst designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP). NEWS - BIOCRYST PHARMACEUTICALS News. View All Hereditary Angioedema (HAE) Galidesivir (BCX4430) RAPIVAB® (peramivir) View All. March 2020 Oral Prophylaxis With Berotralstat (BCX7353) Reduces Use of Standard-of-Care On-Demand Medication in Patients With Hereditary Angioedema: APeX BIOCRYST | ORAL DRUGS FOR RARE DISEASES | PIPELINE BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst’s core development programs include: BCX9930, an oral Factor D inhibitor for the treatment ofcomplement-mediated
BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, SHOWS RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. EVENTS & PRESENTATIONS BioCryst First Quarter 2021 Conference Call. Listen to Webcast. Q1 2021 Earnings Presentation Slides. 158.8 KB. Apr 14, 2021 at 8:45 AM EDT. 20th Annual Needham Virtual Healthcare Conference. Listen to Webcast. Mar 22, 2021 from 9:00 AM to 11:00 AM EDT. BioCryst VirtualR&D Day.
BIOCRYST RECEIVES EUROPEAN COMMISSION APPROVAL OF ORLADEYO RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO ™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “As the first targeted oral prophylactic therapy approved in Europe BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS Data from proof of concept trial expected in 2Q 2020. RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). BIOCRYST’S ORAL FACTOR D INHIBITOR, BCX9930, ADVANCING TO —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— BIOCRYST REPORTS DATA FROM PHASE 1 TRIAL OF BCX9930 AND —Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (pNews
Contact
News
Contact
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0